Fludarabine trials for Breast cancer

All Fludarabine trials · All Breast cancer trials

Phase breakdown

Recruiting trials studying Fludarabine for Breast cancer

• Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
  NCT02830724 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 72 Years · Sex: All (male and female) · 1 location
• Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
  NCT03412877 · Phase: Phase 2 · Ages: 18 Years to 72 Years · Sex: All (male and female) · 2 locations
• Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
  NCT07523529 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours
  NCT07297667 · Phase: Phase 1 · Ages: 15 Years and older · Sex: All (male and female) · 2 locations
• Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
  NCT01174121 · Phase: Phase 2 · Ages: 18 Years to 72 Years · Sex: All (male and female) · 1 location
• Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer
  NCT06121570 · Phase: Phase 1 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer
  NCT06121557 · Phase: Phase 1 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells
  NCT06347068 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer
  NCT05981014 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer
  NCT05981001 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
  NCT04282044 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer
  NCT06532812 · Phase: Phase 1, Phase 2 · Ages: 16 Years to 90 Years · Sex: All (male and female) · 1 location

Common questions

How many trials study Fludarabine for Breast cancer?

12 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.